NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, which will take place from Monday, January 11 through Thursday, Read More
Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity Read More
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2020 – Agendia, Inc., a world leader in precision oncology Read More
Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020
Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., a world Read More
FOCUS Study Shows MammaPrint Accurately Identifies Extremely Indolent Cancers
Findings confirm subanalysis of STO-3 trial and provide foundation for consideration of de-escalation of treatment in post-menopausal patients guided by genomic testing IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., Read More
Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
Co-development program will utilize next-generation digital pathology platform and AI-based technology to provide real-time genomic testing results Partnership to create new products enabling faster access to predictive information in treatment planning for patients with breast Read More